Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study (Q51550717)

From Wikidata

Jump to navigation Jump to search

scientific article published in May 1999

edit

Language	Label	Description	Also known as
English	Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study	scientific article published in May 1999

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11220295

retrieved

6 April 2018

reference URL

http://europepmc.org/abstract/MED/11220295

title

Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11220295

retrieved

6 April 2018

reference URL

http://europepmc.org/abstract/MED/11220295

main subject

type 2 diabetes

0 references

patient

0 references

placebo

1 reference

based on heuristic

inferred from title

(RS)-rosiglitazone

1 reference

based on heuristic

inferred from title

author name string

Patel J

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11220295

retrieved

6 April 2018

reference URL

http://europepmc.org/abstract/MED/11220295

Anderson RJ

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11220295

retrieved

6 April 2018

reference URL

http://europepmc.org/abstract/MED/11220295

Rappaport EB

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11220295

retrieved

6 April 2018

reference URL

http://europepmc.org/abstract/MED/11220295

publication date

1 May 1999

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11220295

retrieved

6 April 2018

reference URL

http://europepmc.org/abstract/MED/11220295

published in

Diabetes, Obesity and Metabolism

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11220295

retrieved

6 April 2018

reference URL

http://europepmc.org/abstract/MED/11220295

volume

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11220295

retrieved

6 April 2018

reference URL

http://europepmc.org/abstract/MED/11220295

issue

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11220295

retrieved

6 April 2018

reference URL

http://europepmc.org/abstract/MED/11220295

page(s)

165-172

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11220295

retrieved

6 April 2018

reference URL

http://europepmc.org/abstract/MED/11220295

cites work

Pathogenesis of NIDDM. A balanced overview

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00020.X

retrieved

21 January 2018

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00020.X

retrieved

21 January 2018

End-stage renal disease attributable to diabetes mellitus

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00020.X

retrieved

21 January 2018

United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00020.X

retrieved

21 January 2018

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00020.X

retrieved

21 January 2018

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00020.X

retrieved

21 January 2018

[[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00020.X

retrieved

21 January 2018

A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00020.X

retrieved

21 January 2018

Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein, PrPC, in cultured cells.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00020.X

retrieved

21 January 2018

The peroxisome proliferator-activated receptors: ligands and activators

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00020.X

retrieved

21 January 2018

Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00020.X

retrieved

21 January 2018

Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00020.X

retrieved

21 January 2018

Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00020.X

retrieved

21 January 2018

Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00020.X

retrieved

21 January 2018

Thiazolidinediones in the treatment of insulin resistance and type II diabetes

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00020.X

retrieved

21 January 2018

Identifiers

DOI

10.1046/J.1463-1326.1999.00020.X

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11220295

retrieved

6 April 2018

reference URL

http://europepmc.org/abstract/MED/11220295

PubMed publication ID

11220295

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11220295

retrieved

6 April 2018

reference URL

http://europepmc.org/abstract/MED/11220295

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51550717&oldid=2276822618"